Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
Sponsor: Novo Nordisk A/S
Summary
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, target engagement, and metabolism of NNC0705-0002 after single and multiple doses in healthy adults. NNC0705-0002 or a placebo (a substance that looks like the study medicine but contains no active medicine), and the treatment they receive may be chosen by chance. NNC0705-0002 is a new medicine that is not yet approved for doctors to prescribe. Depending on the part of the study, participation may last for up to about 7 weeks, including screening, treatment, and follow-up visits.
Official title: A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Target Engagement, and Absorption, Metabolism and Excretion of NNC0705-0002 Following Single and Multiple Oral Administrations of NNC0705-0002 in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2026-09-02
Completion Date
2027-08-01
Last Updated
2026-09-30
Healthy Volunteers
Yes
Interventions
NNC0705-0002
Participants will receive oral capsule of NNC0705-0002.
Placebo
Participants will receive oral capsule of placebo matched to NNC0705-0002.
Locations (1)
ICON - location Groningen
Groningen, Netherlands